Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fares, Wassim
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension	Recruiting	3	234	US	Clofazimine Inhalation Suspension, MNKD-101, Placebo	Mannkind Corporation	MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous	08/26	12/28
ELEVATE, NCT05321420 / 2021-006820-41: LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Active, not recruiting	2	240	Europe, US, RoW	Placebo, Pirfenidone, Deupirfenidone	PureTech, PureTech LYT 100, Inc.	Idiopathic Pulmonary Fibrosis	10/24	12/25